Stockscreener 앱 받기
0.00
100.00%
-2.96
시간 외 거래:
3.05
3.05
+
First Wave BioPharma Inc 주식(FWBI)의 최신 뉴스
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug - Yahoo Finance
XTX Topco Ltd Makes New $657,000 Investment in FirstCash Holdings, Inc. (NASDAQ:FCFS) - Defense World
Dimensional Fund Advisors LP Purchases 15,780 Shares of FirstCash Holdings, Inc. (NASDAQ:FCFS) - Defense World
Seven Eight Capital LP Buys Shares of 20,186 Fortune Brands Innovations, Inc. (NYSE:FBIN) - Defense World
Victory Capital Management Inc. Decreases Stock Holdings in Fortune Brands Innovations, Inc. (NYSE:FBIN) - Defense World
Seven Eight Capital LP Takes Position in FirstCash Holdings, Inc. (NASDAQ:FCFS) - MarketBeat
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Comprehensive Report on the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Inn... - WhaTech
Entero Therapeutics appoints new independent accountant - Investing.com
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report Presents an Inside Look ... - WhaTech
Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray - RTTNews
ENTO stock touches 52-week low at $0.45 amid market challenges - Investing.com
Biopharma Layoff Tracker 2024: Spark, Novartis, Indivior and More Cut Staff - BioSpace
Exocrine Pancreatic Insufficiency Treatment Market 2034: FDA - openPR
Exocrine Pancreatic Insufficiency Treatment Market Report - openPR
Exocrine Pancreatic Insufficiency Market Report Analysis, - openPR
61 Stocks Moving In Thursday's Mid-Day Session - Quantisnow
Entero therapeutics CEO sells shares worth $1,379 - Investing.com India
Entero therapeutics CFO sells shares for tax obligations - Investing.com
Entero therapeutics CFO sells shares for tax obligations By Investing.com - Investing.com India
Stryve Foods issues $505K in convertible notes to fund growth By Investing.com - Investing.com UK
Biotech layoff tracker: 12 biotechs cut over 1,800 jobs in Q2 2024 - The Business Journals
Entero therapeutics CFO sells shares for tax obligations By Investing.com - Investing.com
First Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price ... - Quantisnow
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI) - Quantisnow
AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis - Quantisnow
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary ... - Quantisnow
AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with ... - Quantisnow
AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million - Quantisnow
AzurRx BioPharma to Present at BIO CEO & Investor Digital Conference - Quantisnow
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for ... - Quantisnow
Cash Needed For Phase 3 Celiac Drug Development - Life Science Leader Magazine
Vigil Neuroscience Secures $40M from Sanofi, Bolstering Alzheimer's Drug Development - Quantisnow
Entero Therapeutics appoints new Chief Scientific Officer - Investing.com India
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M - Yahoo Singapore News
Entero Therapeutics appoints new Chief Scientific Officer By Investing.com - Investing.com Canada
Entero Therapeutics appoints new Chief Scientific Officer By Investing.com - Investing.com Australia
Entero Therapeutics appoints new Chief Scientific Officer By Investing.com - Investing.com
Entero Therapeutics appoints new Chief Scientific Officer By Investing.com - Investing.com UK
Entero Therapeutics appoints new Chief Scientific Officer - Investing.com
Exocrine Pancreatic Insufficiency Market to Register Incremental Growth from (2024-2034), Asserts DelveInsight - EIN News
Alzheon Announces Appointment of Renowned Biopharma Executive Gino Santini to Board of Directors - Business Wire
Biotech Stocks: The Top 5 To Watch As Shares Broadly Struggle - Investor's Business Daily
Progress software CFO Anthony Folger sells shares worth over $190,000 - Investing.com
0.87%
자본화:
|
볼륨(24시간):